Advances in the treatment of non-small cell lung cancer in the last decade have been significant. Currently, there are several first-line therapeutic options. The molecular biology of the disease, biomarkers and the patient's clinical characteristics can assist in decision making. The study in question aims to retrospectively evaluate the patterns of choice in the first line treatment of metastatic non-small cell lung cancer without driver mutations, from 2019 to 2022 in 7 centers in Brazil.
Over 18 years old;
Histological diagnosis of advanced non-small cell cancer;
Clinical and demographic data available in medical records;
Patients with localized disease that can be treated locally;
Non-epithelial histology;
small cell carcinoma
neuroendocrine tumor
Patients with a histological diagnosis of advanced non-small cell lung cancer, over 18 years of age
Other
Retrospective
Not listed
treatment regimen decision option one
immunotherapy versus chemotherapy, this outcome will be evaluated based on data from medical records and available laboratory results
treatment regimen decision option two
dual immunotherapy, this outcome will be evaluated based on data from medical records and available laboratory results
Survival analysis
Survival will be analyzed secondarily, using the variable time to death
Click on the lead sponsor to view all of their trials.
D'Or Institute for Research and Education
Lead sponsor
Bristol-Myers Squibb
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
